Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors
作者:Xiaozhang Zheng、Timm Baumeister、Alexandre J. Buckmelter、Maureen Caligiuri、Karl H. Clodfelter、Bingsong Han、Yen-Ching Ho、Nikolai Kley、Jian Lin、Dominic J. Reynolds、Geeta Sharma、Chase C. Smith、Zhongguo Wang、Peter S. Dragovich、Angela Oh、Weiru Wang、Mark Zak、Yunli Wang、Po-wai Yuen、Kenneth W. Bair
DOI:10.1016/j.bmcl.2013.11.006
日期:2014.1
A co-crystal structure of amide-containing compound (4) in complex with the nicotinamide phosphoribosyltransferase (Nampt) protein and molecular modeling were utilized to design and discover a potent novel cyanoguanidine-containing inhibitor bearing a sulfone moiety (5, Nampt Biochemical IC50 = 2.5 nM, A2780 cell proliferation IC50 = 9.7 nM). Further SAR exploration identified several additional c
利用含酰胺化合物(4)与烟酰胺磷酸核糖基转移酶(Nampt)蛋白的共晶体结构和分子建模,设计并发现了一种有效的新型含砜基氰基抑制剂,该抑制剂带有砜部分(5,Nampt Biochemical IC 50 = 2.5nM,A2780细胞增殖IC 50 = 9.7nM。SAR的进一步探索发现了另外几种具有高效能和良好微粒体稳定性的含氰基胍的化合物。其中,化合物15选择用于体内谱分析并在小鼠中证明良好的口服暴露。当在A2780卵巢肿瘤异种移植模型中口服给药时,它还表现出优异的体内抗肿瘤功效。还确定了该化合物与NAMPT蛋白复合的共晶体结构。